



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/709,045
		Filing Date	November 12, 2000
		First Named Inventor	M. Rignon Lentz
		Group Art Unit	1647
		Examiner Name	J. Schwarezkyon
Sheet	2	of	3
		Attorney Docket Number	LEN 102

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
JS		ANDREWS, et al., "Characterization of the receptor for tumor necrosis factor (TNF) and lymphotoxin LT) on human T lymphocytes: TNF and LT differ in their receptor binding properties and the induction of MHC class I proteins on a human CD4+ T cell hybridoma," <i>J Immunol</i> 144:2582-2591 (1990).	/
		CHEN, et al., "Soluble TNF- $\alpha$ receptors are constitutively shed and downregulate adhesion molecule expression in malignant gliomas," <i>J. Neuropathol. Exp. Neural.</i> 56(5):541-550 (1997).	/
		CLACKSON, et al., "Making antibody fragments using phage display libraries," <i>Nature</i> 352:624-688 (1991).	/
		DAUGHERTY, et al., "Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins," <i>Nucl. Acids Res.</i> 19:2471-2476 (1991).	/
		EY, et al., "Isolation of pure IgG <sub>1</sub> , IgG <sub>2a</sub> , and IgG <sub>2b</sub> , immunoglobulins from mouse serum using protein A-Sepharose," <i>Immunochemistry</i> 15:429-436 (1978).	/
		FEINMAN, et al., "Tumor necrosis factor is an important mediator of tumor cell killing by human monocytes," <i>J Immunol</i> 138:635 (1987).	/
		GATANAGA, et al., "Identification of TNF-LT blocking factor(s) in the serum and ultrafiltrates of human cancer patients," <i>Lymphokine Res</i> 9:225-9 (1990).	/
		HARANAKA, et al., "Cytotoxic activity of tumor necrosis factor (TNF) on human cancer cells in vitro," <i>Jpn J Exp Med</i> 51:191 (1981).	/
		Hemostasis and Thrombosis: Basic Principles and Clinical Practice 2nd Ed., Colman, R.W., et al., p. 263 (J.B. Lippincott, Philadelphia, PA 1987).	/
		HOWARD, et al., "Vaccinia virus homologues of the Shope fibroma virus inverted terminal repeat proteins and a discontinuous ORF related to the tumor necrosis factor receptor family," <i>Virology</i> 180:633-664 (1991).	/

Examiner's Signature	<i>g2ell</i>	Date Considered	10/21/02
----------------------	--------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)		Application Number	09/709,045
		O I P E S C I S M A I L D A T E C A N C E L L E D M A R 0 7 2001	
		Filing Date	November 12, 2000
		First Named Inventor & TRADEMARK OFFICE	M. Rignon Lentz
		Group Art Unit	1647
		Examiner Name	J. Seharaseyoun
Sheet	3	of	3
Attorney Docket Number			
LEN 102			

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
/CMW/		JABLONSKA & PEITRUSKA, "Release of soluble tumor necrosis factor receptors from polymorphonuclear cells of breast cancer patients," <i>Arch. Immunol. Ther. Exp. (Warsz)</i> 45(5-6):449-453 (1997).	/
		KABAT, et al., <i>Sequences of Proteins of Immunological Interest</i> 4 <sup>th</sup> Ed. (U.S. Dept. Health and Human Services, Bethesda, MD, 1987).	/
		LANGKOPF, et al., "Soluble tumor necrosis factor receptors as prognostic factors in cancer patients," <i>Lancet</i> 344:57-58 (1994).	/
		MATHIAS, et al., "Activation of the Sphingomyelin signaling pathway intact EL4 cells and in a cell-free system by IL-1b," <i>Science</i> 259:519-522 (1993).	/
		MATSCHINER, et al., <i>Current Advances in Vitamin K Research</i> , pp. 135-140, John W. Suttie, ed. (Elsevier Science Publishing Co., Inc. 1988).	/
		OLD, Antitumor activity of microbial products and tumor necrosis factor, and Bonavida B, et al., (eds): <i>Tumor Necrosis Factor/Cachectin and Related Cytokines</i> , Basell, Karger, p7 (1988).	/
		PHILIP, et al., "Tumor necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, Gamma-interferon and Interleukin-1," <i>Nature</i> 323:86 (1986).	/
		URBAN, et al., "Tumor necrosis factor: A potent effector molecule for tumor cell killing by activated macrophages," <i>Proc Natl Acad Sce USA</i> 83:5233 (1986).	/
/CMW/		ZIEGLER-HEITBROCK, et al., "Tumor necrosis factor as effector molecule in monocyte-mediated cytotoxicity," <i>Cancer Res</i> 46:5947 (1986).	/

Examiner's Signature	<i>G. De Luis</i>	Date Considered	10/2/02
----------------------	-------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

~~Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.~~

**Substitute for form 1449A/PTO**

FEb 26 2007

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**COPY OF PAPERS  
ORIGINALLY FILED**

Sheet 1 of 2

Sheet 1 of 2 Attorney Docket Number LEN 102 Examiner Name S. Senayavaseem

## U.S. PATENT DOCUMENTS

RECEIVED

MAR - 4 2002

TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

Examine  
Signature

Gretl


**Date Considered**

1011 02

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.



Please type a plus sign + inside this box .

Please type a plus sign  inside this box .

• 2007

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

~~Substitute for form 1449A/PTO~~

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

**COPY OF PAPERS** (use as many sheets as necessary)  
**ORIGINALLY FILED**

Sheet 2 of 2

**Complete if Known**

RECEIVED

Application Number	09/709,045	MAR - 4 2002
Filing Date	November 10, 2000	TECH CENTER 1600/2900
First Named Inventor	M. Rigdon Lentz	
Group Art Unit	1647	
Examiner Name	J. Schovasey on	
Attorney Docket Number	LEN 102	

## OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's  
Signature

gels


**Date Considered**

18/11/02

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please ~~use~~ a plus sign (+) inside this box —

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (10-96)

Paper # 11

**Substitute for form 1449A/PTO**

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known	
Application Number	09/709,045
Filing Date	November 10, 2000
First Named Inventor	M. Riggdon Lentz
Group Art Unit	1647
Examiner Name	J. Sehgalayon
Attorney Docket Number	LEN 102

**U.S. PATENT DOCUMENTS**

**RECEIVED**

SEP 04 2002

TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

Examine  
Signature

G. Zehley

**Date Considered**

18116102

*\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.*

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

/Cherie M. Woodward/ 12/13/2011

ATL1 #545995 v1

LEN 102  
077829-00006